-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mirum Pharmaceuticals announced today that the US FDA has approved Livmarli (maralixibat) for the treatment of cholestatic pruritus in children with Alagille syndrome (ALGS) over 1 year old
Alagille syndrome is a rare genetic disease.
Livmarli is an oral selective apical sodium-dependent bile acid transporter (ASBT) inhibitor.
▲The mechanism of action of Livmarli (picture source: Mirum's official website)
The approval of Livmarli is based on the results of a pivotal Phase 2b clinical trial.
Reference materials:
[1] US FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older.
[2] Phase 2 placebo-controlled withdrawal study of the ASBT inhibitor maralixibat in children with Alagille syndrome, Retrieved October 28, 2019, from https://mirumpharma.
(The original text has been deleted)